Washington Has A Powerful New Advocate For Psychedelics

Psychedelic medicines might be on the verge of major regulatory changes in America. And attorney Matt Zorn is behind it.

What’s happening:

• The United States Department of Health and Human Services has officially appointed attorney Matt Zorn as Deputy General Counsel
  

Why it matters:‍

• Matt Zorn has been a highly prominent advocate for reforming drug policy in America, specifically around the therapeutic potential of both cannabis and psychedelics
  

Going deeper:‍

• Matt Zorn has been notably outspoken about bringing sweeping changes to existing drug scheduling in the United States, including previously winning a lawsuit against the Drug Enforcement Administration to allow cannabis research for military veterans with PTSD
  
• Matt Zorn has also previously challenged the Drug Enforcement Administration with lawsuits focused on terminally ill patients being able to access psilocybin assisted therapies under the federal Right to Try laws
  

The intrigue:‍

• Publicly traded psychedelic drug development companies have been continuing to build out clinical infrastructure while awaiting formal approvals from the United States Food and Drug Administration, with Cybin (NYSE: CYBN) recently forming a new partnership with Osmind to prepare for the potential commercial launch of psychedelic assisted therapies in America

‍